ACIU Earnings & Financial Statements
AC Immune S.A.
$2.43
+$0.03(+1.25%)
30
Overall
40
Value
10
Tech
42
Quality
Market Cap
$244.26M
Volume
52.70K
52W Range
$2.10 - $4.00
Target Price
$9.00
ACIU earnings and financial statements: AC Immune S.A.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ACIU Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.57M | $27.31M | $14.80M | $3.94M | - |
| Cost of revenue | - | - | - | $74.78M | - |
| Operating income | -$69.41M | -$52.52M | -$55.11M | -$72.17M | -$80.20M |
| EBITDA | -$67.75M | -$48.62M | -$51.83M | -$68.95M | -$71.10M |
| Net income | -$70.45M | -$50.92M | -$54.23M | -$70.73M | -$72.99M |
| EPS (diluted) | $-0.70 | $-0.51 | $-0.64 | $-0.85 | $-0.97 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $154.25M | $230.91M | $182.81M | $185.94M | $261.44M |
| Total liabilities | $109.37M | $118.64M | $22.17M | $16.95M | $29.46M |
| Shareholders’ equity | $44.88M | $112.27M | $160.64M | $167.18M | $230.19M |
| Cash and equivalents | $26.80M | $36.27M | $78.49M | $31.59M | $82.22M |
| Long-term debt | $3.69M | $4.40M | $2.83M | $2.25M | $2.34M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$69.19M | $65.84M | -$60.41M | -$73.57M | -$65.69M |
| Capital expenditure | - | - | - | -$1.24M | -$2.63M |
| Free cash flow | -$5.49M | -$39.39M | $5.24M | -$74.81M | -$68.32M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACIU | $2.43 | +1.3% | 52.70K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |